Skip to main content

Female Contraception

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Viatris
ViatrisCANONSBURG, PA
1 program
1
Transdermal system containing progestinPhase 31 trial
Active Trials
NCT06672016Active Not Recruiting1,630Est. May 2027
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Bioequivalence Study of Patches With Different Release ProfilesN/A1 trial
Active Trials
NCT00697307Completed43Est. Jul 2003
Bayer
BayerLEVERKUSEN, Germany
1 program
Levonorgestrel IUDN/A1 trial
Active Trials
NCT01833793Completed35Est. May 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
ViatrisTransdermal system containing progestin
BayerLevonorgestrel IUD
Johnson & JohnsonBioequivalence Study of Patches With Different Release Profiles

Clinical Trials (3)

Total enrollment: 1,708 patients across 3 trials

NCT06672016ViatrisTransdermal system containing progestin

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Start: Jan 2025Est. completion: May 20271,630 patients
Phase 3Active Not Recruiting
NCT01833793BayerLevonorgestrel IUD

Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice

Start: Feb 2013Est. completion: May 201535 patients
N/ACompleted
NCT00697307Johnson & JohnsonBioequivalence Study of Patches With Different Release Profiles

Bioequivalence Study of Patches With Different Release Profiles

Start: Mar 2003Est. completion: Jul 200343 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.